Contact

Follow

6174478299

©2019 by FEP Capital Advisors, LLC.

Applying Synthetic Biology To Orphan Drug Development


Officially Founded in Q4 2018, After Operating in Stealth Mode For A Year

 

Detection, Visualization & Orphan Drug Development

Our product candidates are designed to improve detection, visualization and treatment of 3 rare diseases. We plan to file IND's, PMA's and BLA's With the US FDA to support future clinical development.

SB-101 Is designed reduce the frequency of invasive interventions in 3 rare diseases

SB-201 Is a new therapeutic paradigm in treating rare diseases of the GI tract

 

"Big results require big ambitions"

Heraclitus

Petri Dish
 

Want To Learn More?

BloodCells.jpg